Q301--Notice of Intent to Sole Source NATERA Transplant Rejection Surveillance
Veterans Affairs · NETWORK CONTRACT OFFICE 19 (36C259)
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 36C25926Q0660 in this department, oldest first.
- Aug 12, 2026 · this noticeSpecial Notice
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
In accordance with RFO 12.201-1, this Notice of Intent is to inform all parties the Department of Veterans Affairs, Network Contracting Office (NCO) 19 located at 6162 South Willow Drive Suite 300, Greenwood Village, CO 80111 intends to award a sole source procurement for the following requirement to the large business, Natera, Inc., located at 13011 McCallen Pass, Austin, Texas 78752: ITEM # DESCRIPTION OF SUPPLIES QTY UNIT OF ISSUE 0001 Molecular expression transplant assessment testing 225 EA 0002 Molecular Assessment for Kidney Disease 15 EA 0003 Molecular Genetic Prenatal Screening Test 2… (show all)
0 EA Natera Inc. is the sole source for the requested molecular genetic reference testing as the testing is proprietary to Natera. This acquisition will provide reference testing for Natera s Prospera molecular expression transplant assessment testing, Renasight molecular assessment for kidney disease, and Panorama Noninvasive prenatal test (NIPT) molecular genetic prenatal screening tests. The associated North America Classification Systems (NAICS) Code is 621511 and the Business Size Standard is $41.5 Million. THIS NOTICE OF INTENT IS NOT A REQUEST FOR COMPETITIVE QUOTES. Interested parties may identify their interest and capability to respond to this requirement no later than 3:00 PM Mountain Standard Time, Wednesday, August 19th, 2026. Information received in response to this notice must clearly demonstrate the capability of meeting the Government s need as stated above. Include any relevant information (specifications, cut sheets, brochures, capability statement, etc.) confirming the ability to supply the products and/or any services outlined in this notice. Responses to this notice are to be sent to Lindsey.Zwaagstra@va.gov. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. The Government is not responsible for any potential costs incurred from interested parties desiring to respond to this notice.
Who won similar work
3 award notices on SAM.gov in the last 24 months. Matched by: Same office (NETWORK CONTRACT OFFICE 19 (36C259)), same product/service code (PSC) Q301 and NAICS 621511.
Single-winner award sizes (3): middle half $747K to $1.1M, median $1.0M; range $486K to $1.1M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| EXOSOME DIAGNOSTICS INC · $TECH · $1.2B | 1 | $1.1M | Sep 16, 2026 |
| CYTOPATH BIOPSY LAB INC | 1 | $1.0M | Sep 22, 2026 |
| VERACYTE LABS SD CORPORATION · $VCYT · $361.1M | 1 | $486K | May 29, 2026 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- $TECH reported $1.2B revenue in FY2026. The median single-winner award in these 3 past awards, $1.0M, is under 0.1% of that. 10-K
- $VCYT reported $361.1M revenue in FY2025. The median single-winner award in these 3 past awards, $1.0M, is 0.3% of that. 10-K
One award's total value against one year of revenue; many awards are paid over several years.
- Sep 22, 2026CYTOPATH BIOPSY LAB INC$1.0MQ301-- Molecular Thyroid TestingNo listed company matched (Materiality N/A)
- Sep 16, 2026EXOSOME DIAGNOSTICS INC$1.1MQ301--Base Year | 36C259-26-AP-1918 | Prostate Testing Non-Invasive | VISN ContractMateriality: 0.09% of $TECH revenue (Low) SEC
- May 29, 2026VERACYTE LABS SD CORPORATION$486KQ301--5 Year BPA Decipher Prostate TestMateriality: 0.09% of $VCYT revenue (Low) SEC
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
Competitive landscape
For the 3 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Veterans Affairs, Dept of (VA) since 2024 (0 filings)
- 0 of their lobbyists list a past Veterans Affairs, Dept of (VA) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 25 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 2 of the past winners are listed companies
- 0 insider buys and 2 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.